GLPG
Lakefront Biotherapeutics NV
$28.27
+1.58%
No data for this timeframe.
Vol
Inst. Holders6 funds
Inst. Value$18.7M
Inst. Activity1 buys / 1 sells
SEC Reports1
Recent Activity
May 27, 2026
SEC
Bank of America crossed above the 5% threshold and now holds a 9.30% total economic interest in Lakefront Biotherapeutic
6-K — Impact 4/10
Inst.
NORGES BANK — NEW
90,000 shares ($2.9M)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
16,360 shares ($535.0K)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$27.51 (Feb 2026)
Current $27.73
Low $27.51
Median $27.51
High $27.51
1 analysts
$27.51
$27.51
Analyst Ratings
2Strong Buy
1Buy
6Hold
6Sell
3Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 25, 2026 | RBC Capital | MAINTAIN | Sector Perform → Sector Perform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-6.24 ▼ -985.2% | $-11.71 — $-0.77 | -569% YoY | 2 |
| Next Q | $-0.77 ▼ -36.6% | $-0.87 — $-0.66 | -330% YoY | 2 |
| Current FY | $-6.22 ▼ -136.6% | $-14.15 — $-1.18 | -161% YoY | 3 |
| Next FY | $-1.36 ▼ -95.7% | $-4.03 — $0.35 | 78% YoY | 4 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $10.2M | ADD |
| NORGES BANK | $2.9M | NEW |
| MORGAN STANLEY | $2.2M | DOUBLED |
| FMR LLC | $1.9M | NEAR_EXIT |
| BANK OF AMERICA CORP | $1.0M | TRIM |
6 institutional holders with $18.7M total value (573,183 shares) as of 2025-Q4. Top holders: RENAISSANCE, NORGES, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 310,600 | $10.2M | 54.2% | ADD +40.5% |
| 2 | NORGES BANK | 90,000 | $2.9M | 15.7% | NEW |
| 3 | MORGAN STANLEY | 68,285 | $2.2M | 11.9% | DOUBLED +160.4% |
| 4 | FMR LLC | 56,969 | $1.9M | 9.9% | NEAR_EXIT -96.5% |
| 5 | BANK OF AMERICA CORP /DE/ | 30,969 | $1.0M | 5.4% | TRIM -49.2% |
| 6 | TWO SIGMA INVESTMENTS, LP | 16,360 | $535.0K | 2.9% | TRIM -27.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 90,000 | — | $2.9M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 22,459 | 16,360 | -27.2% | $535.0K | 2025-Q4 |
| UBS Group AG | TRIM | 238,524 | 152,999 | -35.9% | $5.3M | 2025-Q3 |
| FMR LLC | NEAR_EXIT | 1,547,028 | 54,011 | -96.5% | $1.9M | 2025-Q3 |
| NORGES BANK | EXIT | 120,000 | 0 | -100.0% | $0.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 330,800 | 464,700 | +40.5% | $13.0M | 2025-Q2 |
| UBS Group AG | DOUBLED | 109,011 | 238,524 | +118.8% | $6.7M | 2025-Q2 |
| NORGES BANK | NEW | — | 120,000 | — | $3.4M | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 25,407 | 66,164 | +160.4% | $1.9M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 59,606 | 30,306 | -49.2% | $848.3K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 49,161 | 21,659 | -55.9% | $606.2K | 2025-Q2 |
| UBS Group AG | ADD | 75,579 | 109,011 | +44.2% | $2.7M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 49,161 | — | $1.2M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 68,473 | 26,800 | -60.9% | $673.2K | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 144,137 | 25,407 | -82.4% | $638.2K | 2025-Q1 |
| NORGES BANK | EXIT | 120,000 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 84,355 | 144,137 | +70.9% | $4.0M | 2024-Q4 |
| UBS Group AG | DOUBLED | 982 | 75,579 | +7596.4% | $2.1M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 113,729 | 84,355 | -25.8% | $2.4M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2026): 17% buy across 18 analysts — 2 strong buy, 1 buy, 6 hold, 6 sell, 3 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$27.51 mean target (Feb 2026)
$27.51 Low
$27.51 High
| Metric | Value |
|---|---|
| Current Price | $27.73 |
| Target Low | $27.51 |
| Target Mean | $27.51 |
| Target Median | $27.51 |
| Target High | $27.51 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-6.24 | $-11.71 | $-0.77 | -569.1% | -985.2% | 0↑ 2↓ | $0.0B | -48.8% | 2 |
| Next Q 2026-09-30 |
$-0.77 | $-0.87 | $-0.66 | -329.8% | -36.6% | 0↑ 2↓ | $0.0B | -53.3% | 2 |
| Current FY 2026-12-31 |
$-6.22 | $-14.15 | $-1.18 | -161.0% | -136.6% | 0↑ 2↓ | $0.3B | -75.5% | 3 |
| Next FY 2027-12-31 |
$-1.36 | $-4.03 | $0.35 | 78.1% | -95.7% | 0↑ 2↓ | $0.2B | -40.3% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-6.240 | |
| 7d ago | $-0.575 | -5.665 |
| 30d ago | $-0.575 | -5.665 |
| 60d ago | $0.280 | -6.520 |
| 90d ago | $0.280 | -6.520 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 25, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 1 | 6 | 6 | 3 | 17% | |
| May 1, 2026 | 2 | 1 | 6 | 6 | 3 | 17% | |
| Apr 1, 2026 | 2 | 1 | 6 | 6 | 3 | 17% | |
| Mar 1, 2026 | 2 | 1 | 6 | 6 | 3 | 17% | |
| Feb 1, 2026 | 2 | 1 | 6 | 7 | 3 | 16% | |
| Jan 1, 2026 | 2 | 1 | 6 | 7 | 3 | 16% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.